Gonadorelin

Gonadorelin is the synthetic form of native gonadotropin-releasing hormone (GnRH), a 10-amino-acid hypothalamic peptide that stimulates release of LH and FSH. It was previously approved in the US as a diagnostic agent and is used in veterinary products.

Last reviewed 2026-10-25 by the PeptideWiki editorial team. Editorial policy.

Overview

Gonadorelin is the name used for synthetic gonadotropin-releasing hormone, the hypothalamic decapeptide that controls the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary. The structure of GnRH was determined in the early 1970s by the groups of Andrew Schally and Roger Guillemin, work recognized by the 1977 Nobel Prize in Physiology or Medicine. Gonadorelin has the same sequence as the native hormone and is the parent compound for the many GnRH agonist and antagonist drugs developed since.

Native GnRH is released in pulses, and the pituitary response depends strongly on that pattern: pulsatile exposure maintains LH and FSH release, whereas continuous exposure leads to receptor desensitization and suppression. This property underlies both the diagnostic use of gonadorelin to test pituitary responsiveness and the development of long-acting analogues for hormone suppression. Gonadorelin has a short half-life in circulation compared with synthetic analogues, which limits its use to settings where brief or pulsed exposure is wanted.

Compare: Gonadorelin vs kisspeptin-10.

Structure

Gonadorelin is a decapeptide with the sequence pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2, with an N-terminal pyroglutamate and a C-terminal glycinamide. Both end modifications are present in the native hormone and protect against exopeptidases. The Gly6 position is the main site modified in synthetic agonists such as triptorelin and leuprolide, where a D-amino acid at position 6 greatly increases stability and receptor potency. Pharmaceutical and research forms include gonadorelin acetate and gonadorelin hydrochloride; veterinary products may use other salts, and the salt affects net peptide content.

Mechanism

Gonadorelin binds the GnRH receptor (GnRHR), a G protein-coupled receptor on pituitary gonadotroph cells that signals mainly through Gq/11, phospholipase C, calcium mobilization and protein kinase C. Receptor activation stimulates the synthesis and release of LH and FSH, which in turn regulate gonadal steroid production and gametogenesis. Intermittent stimulation sustains this response, whereas sustained exposure causes receptor desensitization and internalization, reducing gonadotropin output. GnRH receptors are also found outside the pituitary, though their physiological significance there is less well defined.

Research

Diagnostic testing of the pituitary

Gonadorelin was used clinically as a diagnostic agent to assess the capacity of the pituitary to release LH and FSH, for example in evaluating suspected hypogonadotropic hypogonadism or disorders of puberty. In such tests, gonadotropin levels are measured before and after a single exposure. In the United States this diagnostic product, marketed as Factrel, is no longer available, and other agents or protocols are now generally used for these assessments. Historically, the test helped distinguish pituitary from hypothalamic causes of low gonadotropin levels, although interpretation was not always straightforward and responses overlapped between groups.

Pulsatile GnRH physiology

Research with gonadorelin delivered in pulses established much of what is known about the pulse-frequency coding of the reproductive axis. Studies in animals and in people with hypothalamic forms of hypogonadism showed that restoring physiological pulsatility can re-establish gonadotropin secretion and ovulation, while changes in pulse frequency shift the balance of LH and FSH. This work remains foundational to reproductive endocrinology.

Veterinary reproduction

Gonadorelin is widely used in veterinary products, particularly in cattle, where it forms part of protocols for synchronizing ovulation and managing ovarian cysts in breeding programs. A large applied literature in animal science evaluates conception rates and timing under different protocols. These are veterinary applications and do not translate directly to human medicine. Product labels, approved species and protocols differ by country and should be checked in the relevant veterinary regulatory documentation.

Parent of GnRH analogues

Most current clinical use of the GnRH system relies on modified analogues rather than gonadorelin itself. Agonists such as triptorelin, leuprolide and goserelin are used for sustained suppression, and antagonists such as degarelix, or non-peptide antagonists, block the receptor directly. Gonadorelin remains the reference ligand in receptor pharmacology and the comparator for analogue potency and stability. Comparisons of analogue potency are usually expressed relative to it.

Regulatory status

Gonadorelin was previously approved in the United States as a diagnostic agent (Factrel) but is no longer marketed there for human use. It is used in veterinary products. Its current compounding status should be checked against FDA's bulk drug substance lists and guidance. WADA prohibits GnRH and its analogues, including gonadorelin, under class S2 in males; check the current WADA Prohibited List for the exact wording.

Status changes often. See the regulatory tracker for dated updates.

Quality and identity testing

A certificate of analysis should confirm identity by mass spectrometry, with the observed mass matching the expected mass shown on this page for the pyroglutamate- and amide-terminated decapeptide, and report HPLC purity with the chromatogram. Incomplete pyroglutamate formation, a free C-terminal acid instead of the amide, and racemization are characteristic synthesis-related impurities. The tryptophan residue is susceptible to oxidation, giving species with small mass increases. The salt form, such as acetate or hydrochloride, should be named, and net peptide content reported.

For a walkthrough of each section of a certificate, see how to read a COA.

Storage and stability

Store lyophilized gonadorelin sealed at -20 °C or in refrigerated conditions as indicated on its documentation, protected from light and moisture, and let vials reach room temperature before opening. The tryptophan residue makes it sensitive to light and oxidation, so minimize exposure to air and light. Prepare solutions for lab use in sterile water or buffer, keep them refrigerated for short-term use, aliquot for longer storage at -20 °C or below, and avoid repeated freeze-thaw cycles.

Download the Gonadorelin data sheet (PDF): sequence, masses, expected MS ions and handling on one printable page.

Latest research

Frequently asked questions

Related compounds

• Triptorelin

  Triptorelin is a synthetic decapeptide analogue of gonadotropin-releasing hormone with D-tryptophan at position 6. It is an FDA-approved GnRH agonist (Trelstar and others) used in long-acting formulations to suppress gonadal sex-steroid production.

• Kisspeptin-10

  Kisspeptin-10 is the C-terminal decapeptide of kisspeptin, the product of the KISS1 gene. It activates the kisspeptin receptor (KISS1R, also called GPR54) and is studied as a regulator of gonadotropin-releasing hormone and reproductive hormones.

• Oxytocin

  Oxytocin is a nine-amino-acid peptide hormone made in the hypothalamus and released from the posterior pituitary, with a disulfide-bridged ring structure. It regulates uterine contraction and milk ejection, and synthetic oxytocin (Pitocin) is FDA-approved.

References

1. PubMed: all indexed literature on Gonadorelin
2. ClinicalTrials.gov: registered studies mentioning Gonadorelin